| Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet (NCT07696091) | Reistone Biopharma Company Limited | 2026-07-01 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis. (NCT07543224) | Reistone Biopharma Company Limited | 2026-04-01 |
| A Clinical Study of RSS0343 in Healthy Subjects (NCT07289464) | Reistone Biopharma Company Limited | 2026-01-08 |
| A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis (NCT07158151) | Reistone Biopharma Company Limited | 2025-09-25 |
| Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata (NCT05470413) | Reistone Biopharma Company Limited | 2022-04-18 |
| A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis (NCT05181137) | Reistone Biopharma Company Limited | 2021-11-05 |
| Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (NCT04875169) | Reistone Biopharma Company Limited | 2021-04-30 |
| An Open Label Study of the Effects of SHR1459 in NMOSDs Patients (NCT04670770) | Reistone Biopharma Company Limited | 2021-01-20 |
| Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (NCT04717310) | Reistone Biopharma Company Limited | 2020-12-30 |
| A Phase II Study in Patients With Alopecia Areata (NCT04346316) | Reistone Biopharma Company Limited | 2020-05-13 |
| Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo (NCT04774809) | Reistone Biopharma Company Limited | 2020-01-29 |
| A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis (NCT04162899) | Reistone Biopharma Company Limited | 2019-11-06 |
| A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (NCT03677648) | Reistone Biopharma Company Limited | 2019-05-14 |
| A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. (NCT03675477) | Reistone Biopharma Company Limited | 2019-04-13 |